share_log

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target

坎託·菲茨傑拉德重申增持Catalyst Pharmicals,維持25美元的目標股價
Benzinga ·  2023/06/21 09:59

Cantor Fitzgerald analyst Charles Duncan reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight and maintains $25 price target.

坎託·菲茨傑拉德分析師查爾斯·鄧肯重申增持Catalyst Pharmicals(納斯達克股票代碼:CPRX),並維持25美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論